Does the use of topical dorzolamide hydrochloride limit the role of glaucoma surgery

ABSTRACT

This study was designed to evaluate the efficacy of the recently introduced topical carbonic anhydrase inhibitor. [Dorzolamide Hydrochloride 2% [Trusopt 2%]] as an additional therapeutic agent in selected patients suffering from chronic open angle glaucoma. Forty eight eyes [48] in twenty eight [28] patients were included in this study, that was held at Al-Zahraa University Hospital, 12 males and 16 females, mean age was [46.14 years] [Range from 31-68 years]. They were diagnosed as chronic simple glaucoma, non of them was subjected to previous glaucoma surgery. These patients were divided into three groups, first group [11 eyes] previously using pilocarpine eye drops only, second group [21 eyes], using Beta-blockers and third group [16 eyes], using combination of both pilocarpine and beta blockers. All patients were submitted to complete eye examination. Then topical 2% dorzolamide hydrochloride was given to all patients every 8 hours in addition to their original treatment, and the patients were followed-up for 6 months. The LO.P. reduction, were recorded. In the first group, the mean reduction was 4.04, in the second group was 3.99, in the third group it was 3.45 which is statistically significant in three groups. So we concluded that Dorzolamide Hydrochloride 2% was a useful as adjunctive therapy in control the elevated intraocular pressure, deviation and in stabilizing otherwise inadequately controlled cases